Vital Signs - Whats Top-of-mind Among Industry Executives?


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on April 13, 2009, provides an analysis of feedback on evolving strategies and areas of future interest from members of the pharmaceutical, biotechnology and diagnostics community. Additionally, a company spotlight is provided for Signature Genomic Laboratories, a provider of microarray-based comparative genomic hybridization (aCGH) diagnostic products and services. Reimbursement and regulatory news from the FDA is also provided for March 30, 2009.

Table of Contents

Vital Signs - What’s Top-of-mind Among Industry Executives?Vital Signs: 13 April 2009This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.